MedTrace Logo

Myeloid Cell Reprogramming in Thyroid Carcinoma

NCT03397238 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2022-02-09

No results posted yet for this study

Summary

This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone marrow-derived) in such a way that these immune cells promote tumor growth rather than combat the tumor.

Conditions

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Romana T Netea-Maier · Endocrinologist

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-06
Primary Completion
2019-11-26
Completion
2021-01-05

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03397238 on ClinicalTrials.gov